US · ELV · MEDICAL - HEALTHCARE PLANS
Elevance Health Inc. (ELV) intrinsic value and stock valuation
$394.48as of 2026-11-21 · Mkt cap 85.49B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Elevance Health Inc. DCF and intrinsic value
InvestorsCraft values ELV with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ELV’s statements →
Elevance Health Inc. Graham Number
Graham Number: $337.65d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- CVS Health Corp. (CVS) $80.84
- GSK plc (GSK) $47.76
- Regeneron Pharmaceuticals, Inc. (REGN) $920.69
- Cigna Corporation (CI) $270.90
- Cencora, Inc. (COR) $339.09
- Becton, Dickinson and Company (BDX) $212.78
- IDEXX Laboratories, Inc. (IDXX) $676.21
- Humana Inc. (HUM) $389.91
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $199.1B | $176.8B | $171.3B | $156.6B | $138.6B |
| Operating income | $8.11B | $8.89B | $8.75B | $8.45B | $8.95B |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B | $6.1B |
| EPSd | $25.5M | $25.7M | $25.2M | $24.3M | $24.7M |
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.4B | $8.36B |
| Capital expenditure | -$-1.12B | -$-1.26B | -$-1.3B | -$-1.15B | -$-1.09B |
| Free cash flow | $3.17B | $4.55B | $6.77B | $7.25B | $7.28B |
| Total assets | $121.5B | $116.9B | $108.9B | $102.8B | $97.5B |
| Total debt | $33.2B | $32.7B | $26.7B | $25.8B | $24.9B |
| Net debt | $23.7B | $24.4B | $20.1B | $18.4B | $20B |
| Total equity | $44B | $41.4B | $39.4B | $36.3B | $36.1B |
| Cash and short-term investments | $9.49B | $8.29B | $6.53B | $7.39B | $4.88B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $199.1B | $176.8B | $171.3B | $156.6B | $138.6B |
| Cost of revenue | $148.2B | $127.6B | $124.3B | $116.6B | $102.6B |
| Gross profit | $50.9B | $49.2B | $47B | $40B | $36B |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Other expenses | $42.8B | $40.4B | $38.3B | $31.5B | $27B |
| Operating expenses | $42.8B | $40.4B | $38.3B | $31.5B | $27B |
| Cost and expenses | $191B | $167.9B | $162.6B | $148.1B | $129.7B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $1.4B | $1.19B | $1.03B | $851M | $798M |
| Depreciation and amortization | $1.55B | $1.39B | $1.75B | $1.68B | $1.3B |
| Ebitda | $9.66B | $10.5B | $10.5B | $10.1B | $10B |
| Operating income | $8.11B | $8.89B | $8.75B | $8.45B | $8.95B |
| Total other income/expenses, net | -$-1.4B | -$-984M | -$-1.03B | -$-851M | -$-1.02B |
| Income before tax | $6.71B | $7.9B | $7.72B | $7.6B | $7.93B |
| Income tax expense | $1.05B | $1.93B | $1.72B | $1.71B | $1.83B |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B | $6.1B |
| Weighted average shares outstanding | $221.8M | $232.9M | $233.1M | $240M | $243.8M |
| Weighted average diluted shares outstanding | $221.8M | $232.9M | $237.4M | $242.8M | $246.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $9.49B | $8.29B | $6.53B | $7.39B | $4.88B |
| Net receivables | $15.2B | $13.1B | $12.5B | $11.7B | $9.69B |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $24.7B | $21.3B | $19B | $19.1B | $14.6B |
| Property, plant and equipment, net | $5.13B | $5.22B | $4.94B | $4.92B | $4.55B |
| Goodwill and intangible assets | $39.5B | $40.4B | $35.6B | $34.7B | $34.8B |
| Long-term investments | $38.6B | $37.2B | $36.8B | $33.3B | $34B |
| Total non-current assets | $96.8B | $95.5B | $89.9B | $83.6B | $82.9B |
| Total assets | $121.5B | $116.9B | $108.9B | $102.8B | $97.5B |
| Accounts payable | $17.1B | $15.7B | $16.1B | $15.6B | $13.5B |
| Short-term debt | $1.38B | $2.17B | $2.04B | $1.95B | $2.01B |
| Deferred revenue | $1.49B | $1.51B | $1.4B | $1.11B | $0.00 |
| Total current liabilities | $20B | $19.4B | $19.6B | $18.7B | $15.5B |
| Long-term debt | $31.9B | $30.5B | $24.6B | $23.9B | $22.9B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $1.11B | $1.15B |
| Total non-current liabilities | $57.5B | $56B | $50B | $47.8B | $45.8B |
| Capital lease obligations | $529M | $658M | $685M | $751M | $864M |
| Total liabilities | $77.5B | $75.5B | $69.5B | $66.4B | $61.3B |
| Common stock | $2M | $2M | $2M | $2M | $2M |
| Retained earnings | $35.4B | $33.5B | $31.7B | $29.6B | $27.1B |
| Accumulated other comprehensive income (loss) | -$-451M | -$-1.15B | -$-1.31B | -$-2.49B | -$-178M |
| Total equity | $44B | $41.4B | $39.4B | $36.3B | $36.1B |
| Total investments | $38.6B | $37.2B | $36.8B | $33.3B | $34B |
| Total debt | $33.2B | $32.7B | $26.7B | $25.8B | $24.9B |
| Net debt | $23.7B | $24.4B | $20.1B | $18.4B | $20B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $5.66B | $5.97B | $5.99B | $6.02B | $6.1B |
| Depreciation and amortization | $1.55B | $1.39B | $1.75B | $1.68B | $1.3B |
| Stock-based compensation | $276M | $191M | $289M | $264M | $255M |
| Change in working capital | -$-3.28B | -$-1.72B | -$-535M | $253M | $784M |
| Accounts receivable | -$-2.53B | -$-683M | -$-1.76B | -$-2.51B | -$-2.14B |
| Inventory | $0.00 | $0.00 | $0.00 | $2.51B | $2.14B |
| Accounts payable | -$-720M | -$-272M | $1.64B | $252M | $719M |
| Net cash provided by operating activities | $4.29B | $5.81B | $8.06B | $8.4B | $8.36B |
| Investments in property, plant and equipment | -$-1.12B | -$-1.26B | -$-1.3B | -$-1.15B | -$-1.09B |
| Acquisitions, net | $88M | -$-4.45B | -$-1.55B | -$-649M | -$-3.48B |
| Net cash used for investing activities | -$-1.34B | -$-5.17B | -$-5.57B | -$-4.56B | -$-9.64B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-2.61B | -$-2.9B | -$-2.68B | -$-2.32B | -$-1.9B |
| Dividends paid | -$-1.53B | -$-1.51B | -$-1.4B | -$-1.23B | -$-1.1B |
| Net cash used for financing activities | -$-1.74B | $1.19B | -$-3.35B | -$-1.32B | $423M |
| Net change in cash | $1.2B | $1.76B | -$-861M | $2.51B | -$-861M |
| Cash at end of period | $9.49B | $8.29B | $6.53B | $7.39B | $4.88B |
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.4B | $8.36B |
| Capital expenditure | -$-1.12B | -$-1.26B | -$-1.3B | -$-1.15B | -$-1.09B |
| Free cash flow | $3.17B | $4.55B | $6.77B | $7.25B | $7.28B |
Line items
Line items
Line items
About Elevance Health Inc.
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
- CEO
- Gail Koziara Boudreaux
- Employees
- 97.1K
- Beta
- 0.68
Explore
Frequently asked questions
What is the intrinsic value of Elevance Health Inc. (ELV)?
Elevance Health Inc. (ELV) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ELV undervalued?
ELV trades at a price of $394.48 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.